Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.
Puissant
A
A
Dufies
M
M
Raynaud
S
S
Cassuto
J-P
JP
Auberger
P
P
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D002401:Cathepsin B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology / Q000628:therapy*; D008247:Lysosomes / Q000378:metabolism* / Q000473:pathology*; D009842:Oligopeptides / Q000494:pharmacology*; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*; D034741:RNA, Small Interfering / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001549:Benzamides; D009842:Oligopeptides; D010879:Piperazines; D011743:Pyrimidines; D034741:RNA, Small Interfering; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C533912:CTSB protein, human; D002401:Cathepsin B